MetabolicIn Stock
Semaglutide
GLP-1 Receptor Agonist
5mg · Lyophilised Powder
$99.00
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native GLP-1. Extensive Phase 3 clinical data supports its use as a research model for GLP-1-mediated metabolic signalling pathways.
Form
Lyophilised Powder
Purity
≥99% (HPLC)
Storage
2–8°C / 36–46°F
Use
Research Only
1
Secure checkout via PayID · Free shipping over $150
Research Overview
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% amino acid sequence similarity to native human GLP-1, modified with a C18 fatty acid chain enabling albumin binding and extending half-life to approximately 7 days.
The compound has generated one of the largest clinical trial databases in metabolic research history. The STEP and SUSTAIN trial programmes demonstrated significant dose-dependent effects on body weight and glycaemic parameters respectively.
STEP 1 (Wilding et al., NEJM 2021) — the landmark semaglutide obesity trial — demonstrated a mean body weight reduction of 14.9% over 68 weeks versus 2.4% for placebo, fundamentally shifting the research landscape for pharmacological obesity research.
Research interest extends to semaglutide's apparent cardioprotective effects (SUSTAIN-6 trial), potential neuroprotective properties under investigation, and gut microbiome modulation, making it a multi-system research compound.
Research Use Only
For in vitro research and laboratory use only. Not approved by the TGA, FDA, or any regulatory authority for human or veterinary use. By purchasing, you confirm you are a qualified researcher using this compound solely for lawful scientific research.
